Prelude Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.23M | Sell |
29,658
-2,823
| -9% | -$223K | 0.17% | 145 |
|
|
2025
Q4 | $2.57M | Sell |
32,481
-4,812
| -13% | -$362K | 0.19% | 117 |
|
|
2025
Q3 | $2.44M | Sell |
37,293
-2,130
| -5% | -$104K | 0.19% | 117 |
|
|
2025
Q2 | $1.56M | Buy |
39,423
+1,651
| +4% | +$54K | 0.15% | 169 |
|
|
2025
Q1 | $1.14M | Buy |
37,772
+22,177
| +142% | +$726K | 0.09% | 278 |
|
|
2024
Q4 | $545K | Buy |
+15,595
| New | +$583K | 0.03% | 567 |
|
|
2022
Q4 | – | Sell |
-5,341
| Closed | -$236K | – | 1459 |
|
|
2022
Q3 | $236K | Sell |
5,341
-2,087
| -28% | -$87.9K | 0.01% | 998 |
|
|
2022
Q2 | $275K | Buy |
+7,428
| New | +$280K | 0.01% | 1115 |
|
|
2020
Q4 | – | Sell |
-168
| Closed | -$8K | – | 1615 |
|
|
2020
Q3 | $8K | Sell |
168
-1,246
| -88% | -$69.2K | ﹤0.01% | 1486 |
|
|
2020
Q2 | $83K | Buy |
+1,414
| New | +$78.7K | ﹤0.01% | 1009 |
|
|
2019
Q4 | – | Sell |
-108
| Closed | -$6K | – | 2073 |
|
|
2019
Q3 | $6K | Buy |
+108
| New | +$7.04K | ﹤0.01% | 1544 |
|
|
2019
Q2 | – | Sell |
-1,087
| Closed | -$88K | – | 1885 |
|
|
2019
Q1 | $88K | Buy |
1,087
+692
| +175% | +$44.6K | 0.01% | 966 |
|
|
2018
Q4 | $21K | Sell |
395
-15,779
| -98% | -$805K | ﹤0.01% | 1236 |
|
|
2018
Q3 | $834K | Buy |
+16,174
| New | +$760K | 0.05% | 410 |
|
|
2018
Q1 | – | Sell |
-350
| Closed | -$18K | – | 1609 |
|
|
2017
Q4 | $18K | Sell |
350
-31,979
| -99% | -$1.75M | ﹤0.01% | 1153 |
|
|
2017
Q3 | $1.64M | Buy |
32,329
+27,759
| +607% | +$1.45M | 0.15% | 142 |
|
|
2017
Q2 | $232K | Sell |
4,570
-434
| -9% | -$20.2K | 0.02% | 531 |
|
|
2017
Q1 | $201K | Buy |
5,004
+2,590
| +107% | +$116K | 0.02% | 559 |
|
|
2016
Q4 | $115K | Buy |
2,414
+2,035
| +537% | +$80.5K | 0.01% | 781 |
|
|
2016
Q3 | $14K | Sell |
379
-1,776
| -82% | -$55.6K | ﹤0.01% | 1386 |
|
|
2016
Q2 | $50K | Sell |
2,155
-963
| -31% | -$31.1K | 0.01% | 1004 |
|
|
2016
Q1 | $126K | Sell |
3,118
-6,950
| -69% | -$282K | 0.02% | 684 |
|
|
2015
Q4 | $624K | Buy |
10,068
+2,837
| +39% | +$153K | 0.1% | 229 |
|
|
2015
Q3 | $292K | Buy |
7,231
+121
| +2% | +$6.26K | 0.04% | 442 |
|
|
2015
Q2 | $409K | Sell |
7,110
-500
| -7% | -$31.8K | 0.06% | 356 |
|
|
2015
Q1 | $485K | Buy |
7,610
+26
| +0.3% | +$1.76K | 0.07% | 351 |
|
|
2014
Q4 | $468K | Buy |
+7,584
| New | +$374K | 0.07% | 328 |
|
|
2014
Q2 | – | Sell |
-2,020
| Closed | -$87K | – | 2041 |
|
|
2014
Q1 | $87K | Sell |
2,020
-6,182
| -75% | -$300K | 0.01% | 1066 |
|
|
2013
Q4 | $327K | Buy |
8,202
+1,076
| +15% | +$38.3K | 0.05% | 478 |
|
|
2013
Q3 | $268K | Sell |
7,126
-7,874
| -52% | -$235K | 0.04% | 450 |
|
|
2013
Q2 | $403K | Buy |
+15,000
| New | +$319K | 0.09% | 296 |
|
Other funds holding IONS
VPM
VCM
Prelude Capital Management's IONS Position: Q1 2026 in Review
Prelude Capital Management reduced its Ionis Pharmaceuticals (IONS) stake by 8.7% in Q1 2026, selling an estimated $223K and leaving 29,658 shares worth $2.23M. The position accounts for 0.17% of the portfolio, ranked #145.
Prelude Capital Management first reported a position in IONS in Q2 2013 and has held it in 31 quarters since. The position peaked at $2.57M in Q4 2025. 494 funds tracked by Wall St. Rank hold IONS as of Q1 2026.
- Prelude Capital Management held 29,658 shares of Ionis Pharmaceuticals worth $2.23M as of Q1 2026.
- Prelude Capital Management sold 2,823 Ionis Pharmaceuticals shares in Q1 2026, an estimated $223K.
- Ionis Pharmaceuticals made up 0.17% of Prelude Capital Management's portfolio in Q1 2026, its #145 holding.
- Prelude Capital Management first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 31 quarters since.
- Prelude Capital Management's Ionis Pharmaceuticals position peaked at $2.57M in Q4 2025.
- 494 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.
Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.